Personalis (NASDAQ:PSNL) Trading Up 6.2% – Time to Buy?

Personalis, Inc. (NASDAQ:PSNL) shot up 6.2% during mid-day trading on Tuesday . The company traded as high as $8.89 and last traded at $8.7190. 388,790 shares changed hands during trading, a decline of 70% from the average session volume of 1,293,813 shares. The stock had previously closed at $8.21.

Analyst Ratings Changes

Several brokerages have issued reports on PSNL. Guggenheim raised their price objective on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. HC Wainwright upped their price objective on Personalis from $8.50 to $10.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a research report on Saturday, January 31st. Lake Street Capital restated a “buy” rating and issued a $11.00 price target on shares of Personalis in a research note on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research note on Thursday, January 22nd. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.86.

Personalis Stock Up 4.4%

The stock has a market capitalization of $761.02 million, a price-to-earnings ratio of -9.74 and a beta of 1.98. The business’s 50 day simple moving average is $8.82 and its 200-day simple moving average is $7.77.

Insider Buying and Selling

In other Personalis news, CFO Aaron Tachibana sold 103,668 shares of the business’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the completion of the transaction, the chief financial officer directly owned 164,458 shares in the company, valued at $1,772,857.24. The trade was a 38.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 3.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD lifted its stake in Personalis by 1,332.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,448,585 shares of the company’s stock valued at $11,531,000 after purchasing an additional 1,347,439 shares during the last quarter. Kennedy Capital Management LLC increased its holdings in shares of Personalis by 196.2% during the third quarter. Kennedy Capital Management LLC now owns 1,935,078 shares of the company’s stock worth $12,617,000 after buying an additional 1,281,695 shares in the last quarter. Aberdeen Group plc increased its holdings in shares of Personalis by 36.1% during the fourth quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after buying an additional 861,948 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Personalis by 165.6% in the 2nd quarter. Geode Capital Management LLC now owns 1,365,598 shares of the company’s stock valued at $8,960,000 after acquiring an additional 851,422 shares during the last quarter. Finally, ARK Investment Management LLC boosted its holdings in shares of Personalis by 11.3% during the 3rd quarter. ARK Investment Management LLC now owns 7,910,191 shares of the company’s stock valued at $51,574,000 after acquiring an additional 802,268 shares in the last quarter. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.